254. Porphyria Disease details / Clinical trials / Drug dev / DR info


Clinical trials : 72 Drugs : 53 - (DrugBank : 16) / Drug target genes : 19 - Drug target pathways : 35

Drugs and their primary sponsors and trial info
5-probe cocktail   
   Alnylam Pharmaceuticals
      2018   Phase 1   NCT03505853   Sweden;
A novel synthetic, orally-administered, non-peptide small molecule, which acts as   
   Mitsubishi Tanabe Development America Inc.
      2020   Phase 3   EUCTR2019-004226-16-IT   Australia;Canada;Finland;Germany;Italy;Japan;Norway;Spain;Sweden;United Kingdom;United States;
ALN-60519   
   ALNYLAM PHARMACEUTICALS, INC.
      2018   Phase 3   EUCTR2017-002432-17-IT   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
   Alnylam Pharmaceuticals, Inc.
      2018   Phase 3   EUCTR2017-002432-17-PL   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-002432-17-NL   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-002432-17-FI   Australia;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Taiwan;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-002432-17-DE   Australia;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-002432-17-BG   Australia;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Taiwan;United Kingdom;United States;
      2017   Phase 3   EUCTR2017-002432-17-SE   Australia;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Taiwan;United Kingdom;United States;
      2017   Phase 3   EUCTR2017-002432-17-GB   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      2017   Phase 3   EUCTR2017-002432-17-ES   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      2017   Phase 3   EUCTR2017-002432-17-DK   Australia;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Taiwan;United Kingdom;United States;
      2017   Phase 3   EUCTR2017-002432-17-BE   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      2017   Phase 1;Phase 2   EUCTR2016-002638-54-SE   Sweden;United Kingdom;United States;
      2016   Phase 1;Phase 2   EUCTR2016-002638-54-GB   Sweden;United Kingdom;United States;
      -   Phase 3   EUCTR2017-002432-17-FR   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      -   Phase 3   EUCTR2017-002432-17-CZ   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
ALN-AS1   
   ALNYLAM PHARMACEUTICALS, INC.
      2018   Phase 3   EUCTR2017-002432-17-IT   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
   Alnylam Pharmaceuticals, Inc.
      2018   Phase 3   EUCTR2017-002432-17-PL   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-002432-17-NL   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-002432-17-FI   Australia;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Taiwan;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-002432-17-DE   Australia;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-002432-17-BG   Australia;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Taiwan;United Kingdom;United States;
      2017   Phase 3   EUCTR2017-002432-17-SE   Australia;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Taiwan;United Kingdom;United States;
      2017   Phase 3   EUCTR2017-002432-17-GB   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      2017   Phase 3   EUCTR2017-002432-17-ES   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      2017   Phase 3   EUCTR2017-002432-17-DK   Australia;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Taiwan;United Kingdom;United States;
      2017   Phase 3   EUCTR2017-002432-17-BE   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      2017   Phase 1;Phase 2   EUCTR2016-002638-54-SE   Sweden;United Kingdom;United States;
      2016   Phase 1;Phase 2   EUCTR2016-002638-54-GB   Sweden;United Kingdom;United States;
      -   Phase 3   EUCTR2017-002432-17-FR   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      -   Phase 3   EUCTR2017-002432-17-CZ   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
Afamelanotide   
   Clinuvel Pharmaceuticals Limited
      2012   Phase 3   NCT01605136   United States;
      2011   Phase 3   NCT04578496   -
      2010   Phase 2   NCT01097044   United States;
      2010   -   EUCTR2009-011018-51-IE   Finland;Ireland;Netherlands;United Kingdom;
      2009   Phase 3   NCT00979745   Finland;France;Germany;Ireland;Netherlands;United Kingdom;
      2009   -   EUCTR2009-011018-51-NL   Finland;Ireland;Netherlands;United Kingdom;
      2009   -   EUCTR2009-011018-51-GB   Finland;Ireland;Netherlands;United Kingdom;
      2009   -   EUCTR2009-011018-51-FI   Finland;Ireland;Netherlands;United Kingdom;
      2007   Phase 3   NCT04053270   -
Afamelanotide Implant   
   Clinuvel Pharmaceuticals Limited
      -   -   EUCTR2007-000636-13-DE   France;Germany;Italy;Netherlands;Sweden;United Kingdom;
Aminolevulinic acid   
   Association pour la Recherche en Medecine Interne
      2021   -   NCT04923516   -
CAS # in D.3.9.1 for Sodium Salt. CAS number 1639325-43-1 (Parent Acid)   
   Alnylam Pharmaceuticals, Inc.
      2018   Phase 3   EUCTR2017-002432-17-PL   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-002432-17-NL   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-002432-17-FI   Australia;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Taiwan;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-002432-17-DE   Australia;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-002432-17-BG   Australia;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Taiwan;United Kingdom;United States;
      2017   Phase 3   EUCTR2017-002432-17-SE   Australia;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Taiwan;United Kingdom;United States;
      2017   Phase 3   EUCTR2017-002432-17-GB   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      2017   Phase 3   EUCTR2017-002432-17-ES   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      2017   Phase 3   EUCTR2017-002432-17-DK   Australia;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Taiwan;United Kingdom;United States;
      2017   Phase 3   EUCTR2017-002432-17-BE   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      2017   Phase 1;Phase 2   EUCTR2016-002638-54-SE   Sweden;United Kingdom;United States;
      -   Phase 3   EUCTR2017-002432-17-FR   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      -   Phase 3   EUCTR2017-002432-17-CZ   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
CAS# in D.3.9.1 for Sodium Salt. CAS number 1639325-43-1 (Parent Acid)   
   Alnylam Pharmaceuticals, Inc.
      2016   Phase 1;Phase 2   EUCTR2016-002638-54-GB   Sweden;United Kingdom;United States;
CUV1647   
   CLINUVEL PHARMACUETICALS LTD
      2007   -   EUCTR2007-000636-13-IT   France;Germany;Italy;Netherlands;Sweden;United Kingdom;
   Clinuvel Pharmaceuticals Limited
      2010   -   EUCTR2009-011018-51-IE   Finland;Ireland;Netherlands;United Kingdom;
      2009   -   EUCTR2009-011018-51-NL   Finland;Ireland;Netherlands;United Kingdom;
      2009   -   EUCTR2009-011018-51-GB   Finland;Ireland;Netherlands;United Kingdom;
      2009   -   EUCTR2009-011018-51-FI   Finland;Ireland;Netherlands;United Kingdom;
      2008   Phase 3   EUCTR2007-000636-13-GB   France;Germany;Italy;Netherlands;Sweden;United Kingdom;
      2008   Phase 3   EUCTR2007-000636-13-FR   France;Germany;Italy;Netherlands;Sweden;United Kingdom;
      2008   -   EUCTR2007-000636-13-SE   France;Germany;Italy;Netherlands;Sweden;United Kingdom;
      2008   -   EUCTR2007-000636-13-NL   France;Germany;Italy;Netherlands;Sweden;United Kingdom;
      -   -   EUCTR2007-000636-13-DE   France;Germany;Italy;Netherlands;Sweden;United Kingdom;
Chlorpromazine Hydrochloride   
   Cycle Pharmaceuticals Ltd.
      2016   Phase 1   NCT02943213   South Africa;
Cimetidine   
   Amy K. Dickey, M.D.
      2021   Phase 2   NCT05020184   United States;
Colestipol   
   Brigham and Women's Hospital
      2011   Phase 2/Phase 3   NCT01422915   United States;
Concentration unit: mg milligram(s)   
   Clinuvel Pharmaceuticals Limited
      2009   -   EUCTR2009-011018-51-GB   Finland;Ireland;Netherlands;United Kingdom;
Cysteine hydrochloride   
   Brigham and Women's Hospital
      1996   Phase 3   NCT00004940   -
   FDA Office of Orphan Products Development
      1996   -   NCT00004831   -
Deferasirox   
   University of Texas Southwestern Medical Center
      2008   Phase 3   NCT00599326   United States;
Dersimelagon   
   Mitsubishi Tanabe Development America Inc.
      2020   Phase 3   EUCTR2019-004226-16-IT   Australia;Canada;Finland;Germany;Italy;Japan;Norway;Spain;Sweden;United Kingdom;United States;
   Mitsubishi Tanabe Pharma Development America (MTDA), Inc.
      2022   Phase 3   EUCTR2021-001831-17-ES   Canada;Germany;Japan;Spain;United Kingdom;United States;
      2021   Phase 3   EUCTR2019-004226-16-FI   Australia;Canada;Finland;Germany;Italy;Japan;Norway;Spain;Sweden;United Kingdom;United States;
      2021   Phase 3   EUCTR2019-004226-16-DE   Australia;Canada;Finland;Germany;Italy;Japan;Norway;Spain;Sweden;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004226-16-SE   Australia;Canada;Finland;Germany;Italy;Japan;Norway;Spain;Sweden;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004226-16-GB   Australia;Canada;Finland;Germany;Italy;Japan;Norway;Spain;Sweden;United Kingdom;United States;
      -   Phase 3   EUCTR2021-001831-17-SE   Australia;Canada;Germany;Italy;Japan;Norway;Spain;Sweden;United Kingdom;United States;
      -   Phase 3   EUCTR2021-001831-17-DE   Australia;Canada;Germany;Italy;Japan;Norway;Spain;Sweden;United Kingdom;United States;
      -   Phase 3   EUCTR2019-004226-16-NO   Australia;Canada;Finland;Germany;Italy;Japan;Norway;Spain;Sweden;United Kingdom;United States;
Exjade   
   Assistance Publique - Hôpitaux de Paris
      2011   Phase 2   NCT01284946   France;
Givosiran   
   ALNYLAM PHARMACEUTICALS, INC.
      2018   Phase 3   EUCTR2017-002432-17-IT   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
   Alnylam Pharmaceuticals
      2019   -   NCT04056481   Australia;Belgium;Canada;France;Germany;Luxembourg;Netherlands;Spain;Sweden;United States;
      2018   Phase 1   NCT03505853   Sweden;
      2017   Phase 3   NCT03338816   Australia;Belgium;Bulgaria;Canada;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
   Alnylam Pharmaceuticals, Inc.
      2018   Phase 3   EUCTR2017-002432-17-PL   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-002432-17-NL   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-002432-17-FI   Australia;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Taiwan;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-002432-17-DE   Australia;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-002432-17-BG   Australia;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Taiwan;United Kingdom;United States;
      2017   Phase 3   EUCTR2017-002432-17-SE   Australia;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Taiwan;United Kingdom;United States;
      2017   Phase 3   EUCTR2017-002432-17-GB   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      2017   Phase 3   EUCTR2017-002432-17-ES   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      2017   Phase 3   EUCTR2017-002432-17-DK   Australia;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Taiwan;United Kingdom;United States;
      2017   Phase 3   EUCTR2017-002432-17-BE   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      2017   Phase 1;Phase 2   EUCTR2016-002638-54-SE   Sweden;United Kingdom;United States;
      2016   Phase 1;Phase 2   EUCTR2016-002638-54-GB   Sweden;United Kingdom;United States;
      -   Phase 3   EUCTR2017-002432-17-FR   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;South Africa;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
      -   Phase 3   EUCTR2017-002432-17-CZ   Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
   Fujii Norihisa
      2021   -   JPRN-jRCT2071200074   Japan;
Givosiran (ALN-AS1)   
   Alnylam Pharmaceuticals
      2016   Phase 1/Phase 2   NCT02949830   Sweden;United Kingdom;United States;
      2015   Phase 1   NCT02452372   Sweden;United Kingdom;United States;
Glucose   
   The University of Texas Medical Branch, Galveston
      2014   Phase 2   NCT02180412   United States;
Harvoni   
   Wake Forest University Health Sciences
      2017   Phase 2   NCT03118674   United States;
Heme arginate   
   National Center for Research Resources (NCRR)
      1998   Phase 1   NCT00004398   -
      1998   Phase 1   NCT00004397   -
      1997   Phase 2   NCT00004396   United States;
      1993   Phase 1/Phase 2   NCT00004789   -
Hemin   
   The University of Texas Medical Branch, Galveston
      2014   -   NCT02935400   United States;
Hemin for injection   
   The University of Texas Medical Branch, Galveston
      2015   Phase 2   NCT02922413   United States;
Hydroxychloroquine   
   The University of Texas Medical Branch, Galveston
      2006   Phase 2   NCT01573754   United States;
Isoniazid   
   University of Utah
      2012   -   NCT01550705   United States;
Luteinizing hormone-releasing factor   
   National Center for Research Resources (NCRR)
      1987   -   NCT00004330   United States;
MT-7117   
   Mitsubishi Tanabe Development America Inc.
      2020   Phase 3   EUCTR2019-004226-16-IT   Australia;Canada;Finland;Germany;Italy;Japan;Norway;Spain;Sweden;United Kingdom;United States;
   Mitsubishi Tanabe Pharma Development America (MTDA), Inc.
      2022   Phase 3   EUCTR2021-001831-17-ES   Canada;Germany;Japan;Spain;United Kingdom;United States;
      2021   Phase 3   EUCTR2019-004226-16-FI   Australia;Canada;Finland;Germany;Italy;Japan;Norway;Spain;Sweden;United Kingdom;United States;
      2021   Phase 3   EUCTR2019-004226-16-DE   Australia;Canada;Finland;Germany;Italy;Japan;Norway;Spain;Sweden;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004226-16-SE   Australia;Canada;Finland;Germany;Italy;Japan;Norway;Spain;Sweden;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004226-16-GB   Australia;Canada;Finland;Germany;Italy;Japan;Norway;Spain;Sweden;United Kingdom;United States;
      -   Phase 3   EUCTR2021-001831-17-SE   Australia;Canada;Germany;Italy;Japan;Norway;Spain;Sweden;United Kingdom;United States;
      -   Phase 3   EUCTR2021-001831-17-DE   Australia;Canada;Germany;Italy;Japan;Norway;Spain;Sweden;United Kingdom;United States;
      -   Phase 3   EUCTR2019-004226-16-NO   Australia;Canada;Finland;Germany;Italy;Japan;Norway;Spain;Sweden;United Kingdom;United States;
   Mitsubishi Tanabe Pharma Development America, Inc.
      2021   Phase 3   NCT05005975   Australia;Canada;Germany;Italy;Japan;Norway;Spain;Sweden;United Kingdom;United States;
MT-7117 High Dose   
   Mitsubishi Tanabe Pharma Development America, Inc.
      2020   Phase 3   NCT04402489   Australia;Canada;Finland;Germany;Italy;Japan;Norway;Spain;Sweden;United Kingdom;United States;
MT-7117 Low Dose   
   Mitsubishi Tanabe Pharma Development America, Inc.
      2020   Phase 3   NCT04402489   Australia;Canada;Finland;Germany;Italy;Japan;Norway;Spain;Sweden;United Kingdom;United States;
MT-7117 high dose   
   Mitsubishi Tanabe Pharma Development America, Inc.
      2018   Phase 2   NCT03520036   United States;
MT-7117 low dose   
   Mitsubishi Tanabe Pharma Development America, Inc.
      2018   Phase 2   NCT03520036   United States;
Nle4,D-Phe7]-a-melanocyte stimulating hormone or NDP-a-MSH   
   Clinuvel Pharmaceuticals Limited
      -   -   EUCTR2007-000636-13-DE   France;Germany;Italy;Netherlands;Sweden;United Kingdom;
Nle4-D-Phe7-alpha-MSH   
   CLINUVEL PHARMACUETICALS LTD
      2007   -   EUCTR2007-000636-13-IT   France;Germany;Italy;Netherlands;Sweden;United Kingdom;
Oral Iron   
   Icahn School of Medicine at Mount Sinai
      2016   -   NCT02979249   United States;
Panhematin   
   The University of Texas Medical Branch, Galveston
      2014   Phase 2   NCT02180412   United States;
Phlebotomy   
   The University of Texas Medical Branch, Galveston
      2006   Phase 2   NCT01573754   United States;
Porphobilinogen   
   Association pour la Recherche en Medecine Interne
      2021   -   NCT04923516   -
Questran   
   Guy's & St Thomas' NHS Foundation Trust
      2007   Phase 4   EUCTR2007-002863-28-GB   United Kingdom;
Recombinant human porphobilinogen deaminase (Porphozym)   
   Zymenex A/S
      2003   Phase 2/Phase 3   NCT00418795   United States;
Sterile Normal Saline ( NaCl)   
   Alnylam Pharmaceuticals
      2015   Phase 1   NCT02452372   Sweden;United Kingdom;United States;
Tin mesoporphyrin   
   National Center for Research Resources (NCRR)
      1998   Phase 1   NCT00004398   -
      1998   Phase 1   NCT00004397   -
      1997   Phase 2   NCT00004396   United States;
      1993   Phase 1/Phase 2   NCT00004789   -